Boston Partners Trims Stake in Phreesia, Inc. (NYSE:PHR)

Boston Partners trimmed its stake in Phreesia, Inc. (NYSE:PHR - Free Report) by 15.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,100 shares of the company's stock after selling 10,313 shares during the period. Boston Partners owned 0.10% of Phreesia worth $1,437,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. R Squared Ltd purchased a new stake in Phreesia in the fourth quarter worth about $30,000. BankPlus Trust Department bought a new position in shares of Phreesia during the 4th quarter valued at approximately $34,000. Venturi Wealth Management LLC purchased a new stake in Phreesia in the 4th quarter worth approximately $76,000. Smartleaf Asset Management LLC raised its stake in Phreesia by 154.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 3,442 shares of the company's stock worth $89,000 after acquiring an additional 2,090 shares during the period. Finally, XTX Topco Ltd purchased a new position in Phreesia during the third quarter valued at approximately $247,000. 92.10% of the stock is owned by institutional investors.

Phreesia Price Performance

Shares of PHR traded down $1.10 during mid-day trading on Wednesday, hitting $27.00. 389,974 shares of the stock were exchanged, compared to its average volume of 416,705. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74. The company has a market cap of $1.59 billion, a PE ratio of -18.37 and a beta of 1.03. Phreesia, Inc. has a 52-week low of $17.07 and a 52-week high of $30.53. The firm has a 50-day moving average of $27.40 and a two-hundred day moving average of $24.12.

Remove Ads

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Citigroup raised their price objective on shares of Phreesia from $31.00 to $35.00 and gave the company a "buy" rating in a research report on Friday, January 10th. Robert W. Baird decreased their price target on Phreesia from $34.00 to $30.00 and set an "outperform" rating on the stock in a report on Wednesday, December 11th. JMP Securities restated a "market outperform" rating and issued a $30.00 price objective on shares of Phreesia in a research report on Tuesday, December 10th. Canaccord Genuity Group increased their target price on Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a research report on Thursday, March 13th. Finally, KeyCorp boosted their price target on Phreesia from $28.00 to $30.00 and gave the stock an "overweight" rating in a report on Wednesday, January 8th. Twelve investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $31.33.

Insider Activity at Phreesia

In other news, General Counsel Allison C. Hoffman sold 3,496 shares of Phreesia stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $25.32, for a total value of $88,518.72. Following the completion of the transaction, the general counsel now owns 139,134 shares in the company, valued at approximately $3,522,872.88. The trade was a 2.45 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Evan Roberts sold 2,873 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $26.61, for a total value of $76,450.53. Following the sale, the chief operating officer now owns 779,993 shares in the company, valued at $20,755,613.73. The trade was a 0.37 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 162,442 shares of company stock valued at $4,611,300 over the last 90 days. 5.80% of the stock is owned by corporate insiders.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.